{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.82","upperLimit":"23.49","value":"8.31"},{"comment":"Data not estimable. At the final data cut the upper limit CI was not reached at the previous data cut due to too few events","groupId":"OG001","lowerLimit":"4.63","upperLimit":"NA","value":"13.83"},{"comment":"Data not estimable due to an insufficient number of patients. Only one patient had a best response of confirmed PR or better","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Duration of response (DOR) is defined as the time from the first evidence of confirmed assessment of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) to first confirmed disease progression, or to death due to any cause. The distribution of DOR was summarized using the Kaplan-Meier (K-M) method. The median DOR was estimated from the 50th percentile of the corresponding K-M estimates. The 95% confidence interval for median DOR was constructed using the method of Brookmeyer (Brookmeyer, 1982).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with moderate renal impairment (eGFR ≥30 to \\<45 mL/min/1.73m²) and a starting dose of melflufen of 40 mg.","id":"OG000","title":"Cohort 1a, Melflufen 40 mg"},{"description":"Patients with moderate renal impairment (eGFR ≥30 to \\<45 mL/min/1.73m²) and a starting dose of melflufen of 30 mg.","id":"OG001","title":"Cohort 1b, Melflufen 30 mg"},{"description":"Patients with severe renal impairment (eGFR ≥15 to \\<30 mL/min/1.73m²) and a starting dose of melflufen of 20 mg.","id":"OG002","title":"Cohort 2a, Melflufen 20 mg"}],"paramType":"MEDIAN","populationDescription":"This analysis included patients who achieved a best confirmed response of PR or better.","reportingStatus":"POSTED","timeFrame":"Patients were assessed for response from the first measure of a confirmed response (PR or better) until confirmed progression, death, or initiation of subsequent therapy (maximum duration 127.1 weeks).","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}